ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

The Cancer Letter Wins Awards (12-page issue).

June 13, 2003

HEW Finally Moves On Distribution Of Chemicals

September 7, 1979

In Brief: Holleb To Retire In June As ACS Vice President; Consensus Conference On Neurofibromatosis Set

January 23, 1987

CCRU, CCSP Projects Described; Plans Listed for DRCCA Applications Branch

November 11, 1983

Scientific Process

September 25, 1998

Center Review By Panel, NCI Leading To Changes; Hammer Tells NCAB It Faces “Difficult Decision”

December 13, 1984